Wait, CNN Was Partying With the Iranians in the UK?
Why a Member of Jasmine Crockett's Security Team Was Just Shot and Killed...
Wait, Did This CNN Guest Just Blame the US for the 9/11 Attacks?
This Quote From Gov. Stitt Is NOT Good News Regarding Who He'd Pick...
What These Two Girls Are Laughing About Is Beyond Chilling
Progressive Crackpots Vs. Environmental Wackos
The Road to Tehran Runs Through Baku
The Parent-Led Rebellion Against EdTech
It’s Time to Build America With U.S.-Made Materials
DEI Is Dead. Corporate America Just Hasn’t Admitted It Yet.
Affordability Is Not a Slogan. Democrats Treat It Like One.
From Panic to Therapy: Cycle of Faux Climate Fear
President Donald J. Trump Can Index Capital Gains With Pen
The Unbearable Lightness of Being Gavin Newsom
The First Time in My Life That I Have Come Into Conflict With...
Tipsheet

Rep. Maloney: Republicans Would Reject Cancer Cure

Rep. Maloney: Republicans Would Reject Cancer Cure

On top of being terrorists and hostage takers, Democrat Rep. Carolyn Maloney apparently thinks Republicans hate cancer patients  because they wouldn't budge on tax hikes during the debt debate.

Advertisement

"If President Obama came in with a cure for cancer they would have turned that down, too," she said.

FLASHBACK: Rationing for cancer patients begins through ObamaCare.

A decision to rescind endorsement of the drug would reignite the highly charged debate over US health care reform and how much the state should spend on new and expensive treatments.

Avastin, the world’s best selling cancer drug, is primarily used to treat colon cancer and was approved by the US Food and Drug Administration in 2008 for use on women with breast cancer that has spread.

It costs $8,000 (£5,000) a month and is given to about 17,500 women in the US a year. The drug was initially approved after a study found that, by preventing blood flow to tumours, it extended the amount of time until the disease worsened by more than five months. However, two new studies have shown that the drug may not even extend life by an extra month.

The FDA advisory panel has now voted 12-1 to drop the endorsement for breast cancer treatment. The panel unusually cited "effectiveness" grounds for the decision. But it has been claimed that "cost effectiveness" was the real reason ahead of reforms in which the government will extend health insurance to the poorest.

 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement